Alnylam's Nucresiran Trial for hATTR-PN Evaluates Efficacy Against Vutrisiran
Alnylam Pharmaceuticals is conducting the TRITON-PN study to evaluate the efficacy of Nucresiran in patients with hereditary transthyretin amyloidosis with polyneuropathy. The study aims to assess neurologic impairment and quality of life, while comparing Nucresiran's performance against Vutrisiran,